Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy

Fig. 1

Effect of simvastatin, fluvastatin, or L-OHP alone, and combined treatment with statins and L-OHP on cell viability in KRAS-, BRAF-, or PIK3CA-mutated colorectal cancer cells. a–c LoVo, Colo-205, Caco-2, SW948, HT-29, and Colon-26 cells were administered with the indicated concentrations of a L-OHP, b simvastatin, or c fluvastatin for 1, 3, and 5 days. Cell survival was measured by the WST-8 assay. The results are exemplary five independent experiments. Mean values and S.D. are shown. Statistical analysis was performed by ANOVA with Dunnett’s, and the difference was considered significant when P < 0.05. d LoVo and Colon-26 cells were administered with the showed concentrations of the combined therapy of statins and L-OHP for 3 days. Cell survival was measured by the WST-8 assay. The results are exemplary five independent experiments. Mean values and S.D. are shown. Statistical analysis was performed by ANOVA with Dunnett’s, and the difference was considered significant when P < 0.05. e LoVo and Colon-26 cells were administered with the showed concentrations of the combined therapy of simvastatin and L-OHP for 2 days. Apoptosis was detected using Annexin V-FITC apoptosis detection kit. Mean values and S.D. are shown. The results are exemplary five independent experiments. Statistical analysis was performed by ANOVA with Dunnett’s, and the difference was considered significant when P < 0.05

Back to article page